JP Morgan Chase’s Acer Therapeutics Inc ACER Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-70
| Closed | -$57 | – | 8060 |
|
|
2023
Q3 | $57 | Buy |
70
+22
| +46% | +$18 | ﹤0.01% | 6981 |
|
|
2023
Q2 | $45 | Hold |
48
| – | – | ﹤0.01% | 6750 |
|
|
2023
Q1 | $0 | Hold |
48
| – | – | ﹤0.01% | 7399 |
|
|
2022
Q4 | $0 | Hold |
48
| – | – | ﹤0.01% | 7182 |
|
|
2022
Q3 | $0 | Hold |
48
| – | – | ﹤0.01% | 7006 |
|
|
2022
Q2 | $0 | Hold |
48
| – | – | ﹤0.01% | 7044 |
|
|
2022
Q1 | $0 | Hold |
48
| – | – | ﹤0.01% | 7151 |
|
|
2021
Q4 | $0 | Hold |
48
| – | – | ﹤0.01% | 7085 |
|
|
2021
Q3 | $0 | Hold |
48
| – | – | ﹤0.01% | 6928 |
|
|
2021
Q2 | $0 | Hold |
48
| – | – | ﹤0.01% | 6698 |
|
|
2021
Q1 | $0 | Hold |
48
| – | – | ﹤0.01% | 6456 |
|
|
2020
Q4 | $0 | Hold |
48
| – | – | ﹤0.01% | 6032 |
|
|
2020
Q3 | $0 | Hold |
48
| – | – | ﹤0.01% | 5878 |
|
|
2020
Q2 | $0 | Sell |
48
-16,546
| -100% | -$46.7K | ﹤0.01% | 5791 |
|
|
2020
Q1 | $33K | Sell |
16,594
-2,115
| -11% | -$7.75K | ﹤0.01% | 4842 |
|
|
2019
Q4 | $75K | Buy |
18,709
+17,019
| +1,007% | +$57.8K | ﹤0.01% | 4994 |
|
|
2019
Q3 | $5K | Sell |
1,690
-19,578
| -92% | -$57.4K | ﹤0.01% | 5574 |
|
|
2019
Q2 | $73K | Buy |
21,268
+5,780
| +37% | +$110K | ﹤0.01% | 5038 |
|
|
2019
Q1 | $376K | Buy |
15,488
+6,246
| +68% | +$147K | ﹤0.01% | 4343 |
|
|
2018
Q4 | $186K | Buy |
9,242
+538
| +6% | +$12.4K | ﹤0.01% | 4622 |
|
|
2018
Q3 | $268K | Buy |
8,704
+8,659
| +19,242% | +$232K | ﹤0.01% | 4578 |
|
|
2018
Q2 | $1K | Hold |
45
| – | – | ﹤0.01% | 5503 |
|
|
2018
Q1 | $1K | Sell |
45
-600
| -93% | -$11K | ﹤0.01% | 5329 |
|
|
2017
Q4 | $9K | Buy |
+645
| New | +$10.5K | ﹤0.01% | 5274 |
|
Other funds holding ACER
JP Morgan Chase's ACER Position: Q4 2023 in Review
JP Morgan Chase sold out of Acer Therapeutics Inc (ACER) in Q4 2023, closing a stake of 70 shares — an estimated $57 sold.
JP Morgan Chase first reported a position in ACER in Q4 2017 and held it in 24 quarters. The position peaked at $376K in Q1 2019. 2 funds tracked by Wall St. Rank hold ACER as of Q4 2023.
- JP Morgan Chase reported no remaining Acer Therapeutics Inc position as of Q4 2023 after selling out during the quarter.
- JP Morgan Chase sold 70 Acer Therapeutics Inc shares in Q4 2023, an estimated $57.
- JP Morgan Chase first reported a position in Acer Therapeutics Inc in Q4 2017 and held it in 24 quarters.
- JP Morgan Chase's Acer Therapeutics Inc position peaked at $376K in Q1 2019.
- 2 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q4 2023.
Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.